CA2912313A1 - N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors - Google Patents

N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors

Info

Publication number
CA2912313A1
CA2912313A1 CA2912313A CA2912313A CA2912313A1 CA 2912313 A1 CA2912313 A1 CA 2912313A1 CA 2912313 A CA2912313 A CA 2912313A CA 2912313 A CA2912313 A CA 2912313A CA 2912313 A1 CA2912313 A1 CA 2912313A1
Authority
CA
Canada
Prior art keywords
chloro
sulfonamide
hydroxypyridin
methanesulfonamide
bromo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2912313A
Other languages
English (en)
French (fr)
Inventor
Ingela Fritzson
David LIBERG
Stephen EAST
Colin MACKINNON
Natacha Prevost
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Publication of CA2912313A1 publication Critical patent/CA2912313A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2912313A 2013-05-14 2014-05-14 N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors Abandoned CA2912313A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13167680 2013-05-14
EP13167680.1 2013-05-14
PCT/EP2014/059829 WO2014184234A1 (en) 2013-05-14 2014-05-14 N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors

Publications (1)

Publication Number Publication Date
CA2912313A1 true CA2912313A1 (en) 2014-11-20

Family

ID=48366235

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2912313A Abandoned CA2912313A1 (en) 2013-05-14 2014-05-14 N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors

Country Status (12)

Country Link
US (2) US9873687B2 (https=)
EP (1) EP2925743B1 (https=)
JP (1) JP6322280B2 (https=)
KR (1) KR20160006717A (https=)
CN (1) CN105377837B (https=)
AU (1) AU2014267360B2 (https=)
BR (1) BR112015027395A2 (https=)
CA (1) CA2912313A1 (https=)
EA (1) EA028512B1 (https=)
ES (1) ES2563902T3 (https=)
MX (1) MX360455B (https=)
WO (1) WO2014184234A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020260692A1 (en) * 2019-06-28 2020-12-30 Calprotect Ab Compound for treatment of acute inflammation in the myocardium
CN110407721A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种4-氰基-3-(三氟甲基)苯-1-磺酰氯的合成方法
CN112480106B (zh) * 2020-11-17 2022-09-02 南京海纳医药科技股份有限公司 一种马来酸阿伐曲泊帕杂质的制备方法
CN115974772B (zh) * 2023-01-05 2024-06-14 山东铂源药业股份有限公司 一种利用微通道反应器制备吡啶-3-磺酰氯的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313806A (en) 1963-07-01 1967-04-11 Sumitomo Chemical Co Sulfanilylaminopyridazinone derivatives and method for their production
AU6944696A (en) * 1995-09-14 1997-04-01 Shionogi & Co., Ltd. Novel phenylacetic acid derivatives and medicinal composition containing the same
AU2002358390A1 (en) * 2001-12-18 2003-06-30 Astrazeneca Ab Novel compounds
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
US20060004085A1 (en) * 2002-03-29 2006-01-05 University Of Maryland , Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
SE0301654D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
EP1661889A4 (en) 2003-09-05 2009-08-05 Ono Pharmaceutical Co ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
AU2005316668B2 (en) 2004-12-13 2012-09-06 Millennium Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
AR053992A1 (es) 2004-12-22 2007-05-30 Astrazeneca Ab Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006122723A1 (en) 2005-05-19 2006-11-23 Vaecgene Biotech Gmbh Method for the prevention and/or treatment of autoimmune disease or allogeneic transplant rejections
AU2006283846B2 (en) 2005-08-26 2012-04-05 Merck Serono Sa Pyrazine derivatives and use as PI3K inhibitors
GB0524786D0 (en) * 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
EP2077262A4 (en) 2006-10-23 2011-12-28 Takeda Pharmaceutical IMINOPYRIDINE DERIVATIVE AND USE THEREOF
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos
WO2011023677A1 (en) 2009-08-26 2011-03-03 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
WO2011063339A1 (en) * 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension
AU2011204368B2 (en) 2010-01-06 2014-11-27 Joseph P. Errico Methods and compositions of targeted drug development
US9006433B2 (en) * 2010-04-21 2015-04-14 Merck Sharp & Dohme Corp. Substituted pyrimidines
EP2616450B1 (en) * 2010-09-17 2018-05-02 Kancera AB Sulfonamide compounds

Also Published As

Publication number Publication date
BR112015027395A2 (pt) 2017-08-29
KR20160006717A (ko) 2016-01-19
US20180155330A1 (en) 2018-06-07
EA028512B1 (ru) 2017-11-30
EP2925743A1 (en) 2015-10-07
EA201592166A1 (ru) 2016-05-31
ES2563902T3 (es) 2016-03-16
US20160115158A1 (en) 2016-04-28
MX360455B (es) 2018-11-01
JP6322280B2 (ja) 2018-05-09
MX2015015741A (es) 2016-03-16
EP2925743B1 (en) 2016-02-03
CN105377837B (zh) 2017-08-04
CN105377837A (zh) 2016-03-02
US10125125B2 (en) 2018-11-13
WO2014184234A1 (en) 2014-11-20
AU2014267360A1 (en) 2015-12-17
AU2014267360B2 (en) 2018-07-05
US9873687B2 (en) 2018-01-23
JP2016518428A (ja) 2016-06-23
HK1213254A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
TWI287004B (en) A pyridone derivative having an affinity effect for cannabinoid 2 type receptor
AU2015313782B2 (en) Compounds and compositions as RAF kinase inhibitors
JP2024534526A (ja) ピリジン系誘導体及びその使用
ES2911040T3 (es) Nuevos derivados de heteroaril amida como inhibidores selectivos de histona deacetilasa 1 y 2 (HDAC1/2)
IL225901A (en) Benzamides and nicotinamides as modulators of syc
KR102383938B1 (ko) 신규한 매크로시클릭 화합물
JP6969800B2 (ja) 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体
US10125125B2 (en) N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors
EA025863B1 (ru) Карбазолкарбоксамидные соединения
ES2298853T3 (es) Aroilfuranos y aroiltiofenos apropiados para el tratamiento del cancer.
JP2019515932A (ja) チロシンキナーゼｂｃｒ−ａｂｌ阻害剤としての新規複素環化合物
WO2022135591A1 (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
ES2985416T3 (es) Nuevos compuestos potentes y selectivos como moduladores del receptor de serotonina 1B
WO2017197151A1 (en) Phosphotidylinositol 3-kinase inhibitors
WO2015177367A1 (en) Novel compounds useful as s100-inhibitors
CA2954879C (en) Quinoxaline compounds, method for preparing the same and use thereof
TW202039425A (zh) 雙取代炔類衍生物、包含其之藥物組成及組、及用於製備其之製程
TW200812979A (en) Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
CA3180661A1 (en) Cycloalkyl pyrimidines as ferroportin inhibitors
KR20220156890A (ko) Phd 억제제 화합물, 조성물, 및 용도
HK1213254B (en) N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors
WO2017097215A1 (zh) 内嵌脲类结构的wnt通路抑制剂
WO2025185734A1 (zh) 一种多元螺环化合物的盐及其晶型、其制备方法和医药用途
CN116284043A (zh) 三环类化合物及其医药用途
HK40001081A (en) Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190501

FZDE Discontinued

Effective date: 20210921